The purposes of this study are to investigate the duration of P-glycoprotein inhibition after oral administration of HM30181AK tablet in healthy male subject and proper dose of HM30181AK tablet.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
HM30181AK 1mg tablet
HM30181AK 5mg tablet
HM30181AK 15mg tablet
Seoul National University Hospital
Seoul, South Korea
Evaluate the duration of P-glycoprotein inhibition of HM30181AK by the Loperamide AUC measurement.
Time frame: Day 1~Day 18
Evaluate the PK parameters (Cmax, AUClast, AUCinf, Tmax, T1/2, CL/F etc) of HM30181AK by measuring the blood concentration of HM30181AK
Time frame: Day 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
HM30181AK 60mg tablet
Loperamide 2mg capsule